{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:42:21Z","timestamp":1775050941615,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10975-5","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T13:34:32Z","timestamp":1756906472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of the anticancer effects of doxorubicin-loaded niosomes on HCT-116 cells and the expression levels of LncRNAs DLGAP1-AS1 and AFAP1-AS1 in colorectal cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Neda","family":"Shokri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Kaveh Zenjanab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marziyeh","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Safaralizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"10975_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/mco.2021.2433","volume":"15","author":"S Alzahrani","year":"2021","unstructured":"Alzahrani S, Al Doghaither H, Al\u2013Ghafari A (2021) General insight into cancer: an overview of colorectal cancer (Review). Mol Clin Oncol 15:271. https:\/\/doi.org\/10.3892\/mco.2021.2433","journal-title":"Mol Clin Oncol"},{"key":"10975_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5114\/pg.2018.81072","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterol Rev 14:89\u2013103. https:\/\/doi.org\/10.5114\/pg.2018.81072","journal-title":"Gastroenterol Rev"},{"key":"10975_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/diseases11040148","volume":"11","author":"N Alrushaid","year":"2023","unstructured":"Alrushaid N, Khan FA, Al-Suhaimi E, Elaissari A (2023) Progress and perspectives in colon cancer pathology, diagnosis, and treatments. Diseases 11:148. https:\/\/doi.org\/10.3390\/diseases11040148","journal-title":"Diseases"},{"key":"10975_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155311","volume":"21","author":"OO Ogunwobi","year":"2020","unstructured":"Ogunwobi OO, Mahmood F, Akingboye A (2020) Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci 21:5311. https:\/\/doi.org\/10.3390\/ijms21155311","journal-title":"Int J Mol Sci"},{"key":"10975_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/ijc.34282","volume":"152","author":"M Aprile","year":"2023","unstructured":"Aprile M, Costa V, Cimmino A, Calin GA (2023) Emerging role of oncogenic long noncoding RNA as cancer biomarkers. Int J Cancer 152:822\u2013834. https:\/\/doi.org\/10.1002\/ijc.34282","journal-title":"Int J Cancer"},{"key":"10975_CR6","doi-asserted-by":"publisher","first-page":"154654","DOI":"10.1016\/j.prp.2023.154654","volume":"248","author":"H Akhgari","year":"2023","unstructured":"Akhgari H, Shokri N, Dehghanzadeh P et al (2023) Expression pattern of PCAT1, PCAT2, and PCAT5 LncRNAs and their value as diagnostic biomarkers in patients with gastric cancer. Pathol - Res Pract 248:154654. https:\/\/doi.org\/10.1016\/j.prp.2023.154654","journal-title":"Pathol - Res Pract"},{"key":"10975_CR7","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.2147\/OTT.S237580","volume":"13","author":"C Liu","year":"2020","unstructured":"Liu C, Hou J, Shan F et al (2020) Long non-coding RNA CRNDE promotes colorectal carcinoma cell progression and Paclitaxel resistance by regulating miR-126-5p\/ATAD2 axis. Onco Targets Ther 13:4931\u20134942. https:\/\/doi.org\/10.2147\/OTT.S237580","journal-title":"Onco Targets Ther"},{"key":"10975_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s13577-020-00388-w","volume":"33","author":"W Chen","year":"2020","unstructured":"Chen W, Tu Q, Yu L et al (2020) LncRNA ADAMTS9-AS1, as prognostic marker, promotes cell proliferation and EMT in colorectal cancer. Hum Cell 33:1133\u20131141. https:\/\/doi.org\/10.1007\/s13577-020-00388-w","journal-title":"Hum Cell"},{"key":"10975_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/gtmb.2023.0676","volume":"28","author":"N Sadi Khosroshahi","year":"2024","unstructured":"Sadi Khosroshahi N, Koulaeizadeh S, Abdi A et al (2024) Upregulation of long noncoding RNA PCAT1 in Iranian patients with colorectal cancer and its performance as a potential diagnostic biomarker. Genet Test Mol Biomarkers 28:65\u201369. https:\/\/doi.org\/10.1089\/gtmb.2023.0676","journal-title":"Genet Test Mol Biomarkers"},{"key":"10975_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12397","author":"F Zhang","year":"2018","unstructured":"Zhang F, Li J, Xiao H et al (2018) AFAP1\u2010AS1: a novel oncogenic long non\u2010coding RNA in human cancers. Cell Prolif. https:\/\/doi.org\/10.1111\/cpr.12397","journal-title":"Cell Prolif"},{"key":"10975_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s43042-021-00194-5","volume":"22","author":"S Ghalib Ibrahim Alnajar","year":"2021","unstructured":"Ghalib Ibrahim Alnajar S, Rajabi A, Maydanchi M et al (2021) Overexpression of lncRNA AFAP1-AS1 as a diagnostic biomarker in non-small cell lung cancer. Egypt J Med Hum Genet 22:76. https:\/\/doi.org\/10.1186\/s43042-021-00194-5","journal-title":"Egypt J Med Hum Genet"},{"key":"10975_CR12","doi-asserted-by":"publisher","first-page":"12129","DOI":"10.18632\/aging.202923","volume":"13","author":"L Liu","year":"2021","unstructured":"Liu L, Li X, Shi Y, Chen H (2021) Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297\/EZH2 axis. Aging 13:12129\u201312142. https:\/\/doi.org\/10.18632\/aging.202923","journal-title":"Aging"},{"key":"10975_CR13","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.2174\/0929867329666220919114919","volume":"30","author":"F Zhao","year":"2023","unstructured":"Zhao F, Tan F, Tang L et al (2023) Long non-coding RNA DLGAP1-AS1 and DLGAP1-AS2: two novel oncogenes in multiple cancers. Curr Med Chem 30:2822\u20132834. https:\/\/doi.org\/10.2174\/0929867329666220919114919","journal-title":"Curr Med Chem"},{"key":"10975_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S Gavas","year":"2021","unstructured":"Gavas S, Quazi S, Karpi\u0144ski TM (2021) Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett 16:173. https:\/\/doi.org\/10.1186\/s11671-021-03628-6","journal-title":"Nanoscale Res Lett"},{"key":"10975_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2021035650","volume":"38","author":"S Dahiya","year":"2021","unstructured":"Dahiya S, Dahiya R, Hern\u00e1ndez E (2021) Nanocarriers for anticancer drug targeting: recent trends and challenges. Crit Rev Ther Drug Carr Syst 38:49\u2013103. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2021035650","journal-title":"Crit Rev Ther Drug Carr Syst"},{"key":"10975_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/pharmaceutics14040883","volume":"14","author":"SZ Alshawwa","year":"2022","unstructured":"Alshawwa SZ, Kassem AA, Farid RM et al (2022) Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics 14:883. https:\/\/doi.org\/10.3390\/pharmaceutics14040883","journal-title":"Pharmaceutics"},{"key":"10975_CR17","doi-asserted-by":"publisher","DOI":"10.32474\/DDIPIJ.2018.01.000125","volume":"1","author":"D Louis","year":"2018","unstructured":"Louis D (2018) An overview on niosomes: a drug nanocarrier. Drug Designing & Intellectual Properties International Journal 1:000125. https:\/\/doi.org\/10.32474\/DDIPIJ.2018.01.000125","journal-title":"Drug Designing & Intellectual Properties International Journal"},{"key":"10975_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","volume":"144","author":"S Chen","year":"2019","unstructured":"Chen S, Hanning S, Falconer J et al (2019) Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm 144:18\u201339. https:\/\/doi.org\/10.1016\/j.ejpb.2019.08.015","journal-title":"Eur J Pharm Biopharm"},{"key":"10975_CR19","doi-asserted-by":"publisher","first-page":"49463","DOI":"10.1039\/C7RA07834J","volume":"7","author":"MH Nematollahi","year":"2017","unstructured":"Nematollahi MH, Pardakhty A, Torkzadeh-Mahanai M et al (2017) Changes in physical and chemical properties of niosome membrane induced by cholesterol: a promising approach for niosome bilayer intervention. RSC Adv 7:49463\u201349472. https:\/\/doi.org\/10.1039\/C7RA07834J","journal-title":"RSC Adv"},{"key":"10975_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","volume":"22","author":"M Cagel","year":"2017","unstructured":"Cagel M, Grotz E, Bernabeu E et al (2017) Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discov Today 22:270\u2013281. https:\/\/doi.org\/10.1016\/j.drudis.2016.11.005","journal-title":"Drug Discov Today"},{"key":"10975_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116405","volume":"461","author":"A Elfadadny","year":"2023","unstructured":"Elfadadny A, Ragab RF, Hamada R et al (2023) Natural bioactive compounds-doxorubicin combinations targeting topoisomerase II-alpha: anticancer efficacy and safety. Toxicol Appl Pharmacol 461:116405. https:\/\/doi.org\/10.1016\/j.taap.2023.116405","journal-title":"Toxicol Appl Pharmacol"},{"key":"10975_CR22","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2022_89-310","volume":"89","author":"S Shinji","year":"2022","unstructured":"Shinji S, Yamada T, Matsuda A et al (2022) Recent advances in the treatment of colorectal cancer: a review. J Nippon Med Sch 89:JNMS.2022_89\u2013310. https:\/\/doi.org\/10.1272\/jnms.JNMS.2022_89-310","journal-title":"J Nippon Med Sch"},{"key":"10975_CR23","doi-asserted-by":"publisher","first-page":"18648","DOI":"10.18632\/oncotarget.24307","volume":"9","author":"G Hu","year":"2018","unstructured":"Hu G, Niu F, Humburg BA et al (2018) Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget 9:18648\u201318663. https:\/\/doi.org\/10.18632\/oncotarget.24307","journal-title":"Oncotarget"},{"key":"10975_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01542","author":"Q He","year":"2020","unstructured":"He Q, Long J, Yin Y et al (2020) Emerging roles of lncRNAs in the formation and progression of colorectal cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.01542","journal-title":"Front Oncol"},{"key":"10975_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/CBM-171011","volume":"22","author":"L Liu","year":"2018","unstructured":"Liu L, Meng T, Yang X-H et al (2018) Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion. Cancer Biomark 22:283\u2013299. https:\/\/doi.org\/10.3233\/CBM-171011","journal-title":"Cancer Biomark"},{"key":"10975_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7150\/jca.28780","volume":"10","author":"J Cai","year":"2019","unstructured":"Cai J, Zuo X, Chen Z et al (2019) Long noncoding RNAs serve as potential diagnostic biomarkers for colorectal cancer. J Cancer 10:611\u2013619. https:\/\/doi.org\/10.7150\/jca.28780","journal-title":"J Cancer"},{"key":"10975_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00562-y","volume":"6","author":"Y Zhong","year":"2021","unstructured":"Zhong Y, Yang L, Xiong F et al (2021) Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc. Signal Transduct Target Ther 6:240. https:\/\/doi.org\/10.1038\/s41392-021-00562-y","journal-title":"Signal Transduct Target Ther"},{"key":"10975_CR28","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.3892\/ol.2018.8266","volume":"15","author":"F Ye","year":"2018","unstructured":"Ye F, Gong Y, Chen X et al (2018) Long noncoding AFAP1-antisense RNA 1 is upregulated and promotes tumorigenesis in gastric cancer. Oncol Lett 15:7523\u20137530. https:\/\/doi.org\/10.3892\/ol.2018.8266","journal-title":"Oncol Lett"},{"key":"10975_CR29","doi-asserted-by":"publisher","unstructured":"Li L, Lai Q, Zhang M, Jia J (2021) Long non-coding RNA DLGAP1-AS1 promotes the progression of gastric cancer via miR-515-5p \/ MARK4 axis. 54:1\u20139. https:\/\/doi.org\/10.1590\/1414-431X2020e10062","DOI":"10.1590\/1414-431X2020e10062"},{"key":"10975_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01394","author":"B Fu","year":"2018","unstructured":"Fu B, Wang N, Tan H-Y et al (2018) Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: a review on experimental and clinical evidences. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.01394","journal-title":"Front Pharmacol"},{"key":"10975_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2174\/1573394716666191216114950","volume":"16","author":"M Vyas","year":"2020","unstructured":"Vyas M, Simbo DA, Mursalin M et al (2020) Drug delivery approaches for doxorubicin in the management of cancers. Curr Cancer Ther Rev 16:320\u2013331. https:\/\/doi.org\/10.2174\/1573394716666191216114950","journal-title":"Curr Cancer Ther Rev"},{"key":"10975_CR32","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.2174\/0115672018269199231121055548","volume":"21","author":"S Saharawat","year":"2024","unstructured":"Saharawat S, Verma S (2024) A comprehensive review on niosomes as a strategy in targeted drug delivery: pharmaceutical, and herbal cosmetic applications. Curr Drug Deliv 21:1460\u20131473. https:\/\/doi.org\/10.2174\/0115672018269199231121055548","journal-title":"Curr Drug Deliv"},{"key":"10975_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179668","volume":"23","author":"BA Witika","year":"2022","unstructured":"Witika BA, Bassey KE, Demana PH et al (2022) Current advances in specialised niosomal drug delivery: manufacture, characterization and drug delivery applications. Int J Mol Sci 23:9668. https:\/\/doi.org\/10.3390\/ijms23179668","journal-title":"Int J Mol Sci"},{"key":"10975_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A et al (2021) Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 139:111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708","journal-title":"Biomed Pharmacother"},{"key":"10975_CR35","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.2174\/1871520621666201229115612","volume":"21","author":"L Zhu","year":"2021","unstructured":"Zhu L, Lin M (2021) The synthesis of Nano-Doxorubicin and its anticancer effect. Anticancer Agents Med Chem 21:2466\u20132477. https:\/\/doi.org\/10.2174\/1871520621666201229115612","journal-title":"Anticancer Agents Med Chem"},{"key":"10975_CR36","doi-asserted-by":"publisher","first-page":"s11","DOI":"10.5530\/ijper.55.1s.34","volume":"55","author":"MG Umbarkar","year":"2021","unstructured":"Umbarkar MG (2021) Niosome as a novel pharmaceutical drug delivery: a brief review highlighting formulation, types, composition and application. Indian J Pharm Educ Res 55:s11\u2013s28. https:\/\/doi.org\/10.5530\/ijper.55.1s.34","journal-title":"Indian J Pharm Educ Res"},{"key":"10975_CR37","doi-asserted-by":"publisher","first-page":"055015","DOI":"10.1088\/1748-605X\/ad5d9b","volume":"19","author":"M Sharifi-Azad","year":"2024","unstructured":"Sharifi-Azad M, Kaveh Zenjanab M, Shahpouri M et al (2024) Codelivery of methotrexate and silibinin by niosome nanoparticles for enhanced chemotherapy of CT26 colon cancer cells. Biomed Mater 19:055015. https:\/\/doi.org\/10.1088\/1748-605X\/ad5d9b","journal-title":"Biomed Mater"},{"key":"10975_CR38","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1021\/acsomega.3c09782","volume":"9","author":"M Kaveh Zenjanab","year":"2024","unstructured":"Kaveh Zenjanab M, Abdolahinia ED, Alizadeh E et al (2024) Hyaluronic acid-targeted niosomes for effective breast cancer chemostarvation therapy. ACS Omega 9:10875\u201310885. https:\/\/doi.org\/10.1021\/acsomega.3c09782","journal-title":"ACS Omega"},{"key":"10975_CR39","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/jbm.a.37086","volume":"109","author":"M Hedayati Ch","year":"2021","unstructured":"Hedayati Ch M, Abolhassani Targhi A, Shamsi F et al (2021) Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug\u2010resistant clinical strains of <\u2009scp\u2009> Pseudomonas aeruginosa. J Biomed Mater Res Part A 109:966\u2013980. https:\/\/doi.org\/10.1002\/jbm.a.37086","journal-title":"J Biomed Mater Res Part A"},{"key":"10975_CR40","doi-asserted-by":"publisher","first-page":"19350","DOI":"10.1038\/s41598-021-98638-w","volume":"11","author":"M Soltani","year":"2021","unstructured":"Soltani M, Souri M, Moradi Kashkooli F (2021) Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. Sci Rep 11:19350. https:\/\/doi.org\/10.1038\/s41598-021-98638-w","journal-title":"Sci Rep"},{"key":"10975_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122845","volume":"637","author":"S Saharkhiz","year":"2023","unstructured":"Saharkhiz S, Zarepour A, Zarrabi A (2023) A new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast cancer. Int J Pharm 637:122845. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122845","journal-title":"Int J Pharm"},{"key":"10975_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/metabo12111047","volume":"12","author":"R Ganesan","year":"2022","unstructured":"Ganesan R, Prabhakaran V-S, Valsala Gopalakrishnan A (2022) Metabolomic signatures in doxorubicin-induced metabolites characterization, metabolic inhibition, and signaling pathway mechanisms in colon cancer HCT116 cells. Metabolites 12:1047. https:\/\/doi.org\/10.3390\/metabo12111047","journal-title":"Metabolites"},{"key":"10975_CR43","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.xphs.2019.03.020","volume":"108","author":"P Kulkarni","year":"2019","unstructured":"Kulkarni P, Rawtani D (2019) Application of Box-Behnken design in the preparation, optimization, and in vitro evaluation of self-assembly e based Tamoxifen- and Doxorubicin-loaded and dual drug e loaded niosomes for combinatorial breast cancer treatment. J Pharm Sci 108:2643\u20132653. https:\/\/doi.org\/10.1016\/j.xphs.2019.03.020","journal-title":"J Pharm Sci"},{"key":"10975_CR44","doi-asserted-by":"publisher","first-page":"107673","DOI":"10.1016\/j.toxicon.2024.107673","volume":"241","author":"P Honari","year":"2024","unstructured":"Honari P, Shahbazzadeh D, Behdani M, Pooshang Bagheri K (2024) Highly in vitro anti-cancer activity of melittin-loaded niosomes on non-small cell lung cancer cells. Toxicon 241:107673. https:\/\/doi.org\/10.1016\/j.toxicon.2024.107673","journal-title":"Toxicon"},{"key":"10975_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.36346\/sarjms.2019.v01i01.004","volume":"01","author":"DSN Agrawal","year":"2019","unstructured":"Agrawal DSN (2019) The vital phenomena of apoptosis: a review. South Asian Res J Med Sci 01:15\u201319. https:\/\/doi.org\/10.36346\/sarjms.2019.v01i01.004","journal-title":"South Asian Res J Med Sci"},{"key":"10975_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/mmr.2022.12898","volume":"27","author":"D Hu","year":"2022","unstructured":"Hu D, Meng R, Nguyen T et al (2022) Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway. Mol Med Rep 27:11. https:\/\/doi.org\/10.3892\/mmr.2022.12898","journal-title":"Mol Med Rep"},{"key":"10975_CR47","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.prp.2018.08.014","volume":"214","author":"D Ji","year":"2018","unstructured":"Ji D, Zhong X, Jiang X et al (2018) The role of long non-coding RNA AFAP1-AS1 in human malignant tumors. Pathology 214:1524\u20131531. https:\/\/doi.org\/10.1016\/j.prp.2018.08.014","journal-title":"Pathology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10975-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10975-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10975-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:05:14Z","timestamp":1766898314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10975-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10975"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10975-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Medical Ethics Committee of the University of Tabriz (IR.TABRIZU.REC.1404.026).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have provided their explicit consent for the publication of this manuscript in this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"864"}}